Palliative and supportive care for renal cancer

Renal Cell Carcinoma: Clinical Management

Volumn , Issue , 2013, Pages 339-348

  Parala Metz, Armida ^a   Davis, Mellar ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896727179     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-62703-062-5_19     Document Type: Chapter

References (84)

1. Harding G, Cella D, Robinson Jr D, Mahadevia PJ, Clark J, Revicki DA. Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index. Health Qual Life Outcomes. 2007;5:34.
2. Eton DT, Cella D, Bacik J, Motzer RJ. A brief symptom index for advanced renal cell carcinoma. Health Qual Life Outcomes. 2006;4:68.
3. Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, Chen I, Motzer RJ. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol. 2008;26(22):3763-9.
4. Turner JS, Cheung EM, George J, Quinn DI. Pain management, supportive and palliative care in patients with renal cell carcinoma. BJU Int. 2007;99(5 Pt B):1305-12.
5. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330(9):592-6.
6. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, Cohen R, Dow L. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8): 1420-33.
7. Maessen M, Veldink JH, van den Berg LH, Schouten HJ, van der Wal G, Onwuteaka-Philipsen BD. Requests for euthanasia: origin of suffering in ALS, heart failure, and cancer patients. J Neurol. 2010;257(7):1192-8.
8. Ripamonti C, Bandieri E. Pain therapy. Crit Rev Oncol Hematol. 2009;70(2):145-59.
9. Twycross R, Wilcock A. Hospice and palliative care formulary USA. 2nd ed. UK: Palliativedugs.com Ltd; 2008. pp. 219, 363-72.
10. Quigley C. The role of opioids in cancer pain. BMJ. 2005;331(7520):825-9.
11. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Expert Working Group of the Research Network of the European Association for Palliative Care. Br J Cancer. 2001;84(5):587-93.
12. Walsh D, Rivera NI, Davis MP, Lagman R, Legrand SB. Strategies for pain management: Cleveland Clinic Foundation guidelines for opioid dosing for cancer pain. Support Cancer Ther. 2004;1(3):157-64.
13. Payne R. Recognition and diagnosis of breakthrough pain. Pain Med. 2007;8 Suppl 1:S3-7.
14. Davis MP. Recent development in therapeutics for breakthrough pain. Expert Rev Neurother. 2010;10(5):757-73.
15. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care. 2009;3(1):1-6.
16. Fine PG, Portenoy RK. Ad hoc expert panel on evidence review and guidelines for opioid rotation. establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38(3):418-25.
17. Vadalouca A, Moka E, Argyra E, Sikioti P, Siafaka I. Opioid rotation in patients with cancer: a review of the current literature. J Opioid Manag. 2008;4(4):213-50.
18. Vissers KC, Besse K, Hans G, Devulder J, Morlion B. Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract. 2010;10(2):85-93.
19. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995;10(5): 378-84.
20. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32(4):304-15.
21. Müller-Busch HC, Lindena G, Tietze K, Woskanjan S. Opioid switch in palliative care, opioid choice by clinical need and opioid availability. Eur J Pain. 2005;9(5):571-9.
22. Knotkova H, Pappagallo M. Adjuvant analgesics. Med Clin North Am. 2007;91(1):113-24.
23. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V. Strategies to manage the adverse effects of oral morphine: an evidence-based report. Expert Working Group of the European Association of Palliative Care Network. J Clin Oncol. 2001;19(9):2542-54.
24. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59(4):850-6.
25. Schug SA, Zech D, Dörr U. Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage. 1990;5(1):27-32.
26. Grond S, Zech D, Schug SA, Lynch J, Lehmann KA. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage. 1991;6(7):411-22.
27. Watanabe A, Yamakage M. Intrathecal neurolytic block in a patient with refractory cancer pain. J Anesth. 2011;25:603-5.
28. Joshi M, Chambers WA. Pain relief in palliative care: a focus on interventional pain management. Expert Rev Neurother. 2010;10(5):747-56.
29. Chambers WA. Nerve blocks in palliative care. Br J Anaesth. 2008;101(1):95-100.
30. Dy SM. Evidence-based approaches to pain in advanced cancer. Cancer J. 2010;16(5):500-6.
31. Eleraky M, Papanastassiou I, Vrionis FD. Management of metastatic spine disease. Curr Opin Support Palliat Care. 2010;4(3):182-8.
32. Nazario J, Tam AL. Ablation of bone metastases. Surg Oncol Clin N Am. 2011;20(2):355-68. ix.
33. Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer. 1993;71(4):1309-12.
34. Fahn HJ, Lee YH, Chen MT, Huang JK, Chen KK, Chang LS. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol. 1991;145(2):248-50.
35. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373-9.
36. Takahashi S, Hakuta M, Aiba K, Ito Y, Horikoshi N, Miura M, Hatake K, Ogata E. Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels. Endocr Relat Cancer. 2003;10(3):403-7.
37. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol. 2002;4(4):163-70.
38. Mundy GR, Guise TA. Hypercalcemia of malignancy. Am J Med. 1997;103(2):134-45.
39. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85(9):838-54.
40. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med. 2008;149(4):259-63.
41. Lumachi F, Brunello A, Roma A, Basso U. Cancer-induced hypercalcemia. Anticancer Res. 2009;29(5): 1551-5.
42. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032-45.
43. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19(1):80-100.
44. Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep. 2009;7(1):18-22.
45. Castellano D, Sepulveda JM, García-Escobar I, Rodriguez-Antolín A, Sundlöv A, Cortes-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011;16(2):136-45.
46. Polascik TJ. Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther. 2009;3: 27-40.
47. Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol. 2001;19(2):379-82.
48. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860-7.
49. Saad F, Eastham JA. Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol. 2010;37 Suppl 1:S38-44.
50. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150-7.
51. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nons-mall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613-21.
52. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98(5):962-9.
53. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19(3): 420-32.
54. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9 Suppl 4:28-37.
55. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. Task force on bisphosphonate-related osteonecrosis of the jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update. Aust Endod J. 2009;35(3):119-30.
56. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci. 2011;1218(1):47-54.
57. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23(6):826-36.
58. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17(6):897-907.
59. Sarhill N, Mahmoud F, Walsh D, Nelson KA, Komurcu S, Davis M, LeGrand S, Abdullah O, Rybicki L. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer. 2003;11(10):652-9.
60. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass Jr HO, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69(4):491-7.
61. Loprinzi CL, Laurie JA, Wieand HS, Krook JE, Novotny PJ, Kugler JW, Bartel J, Law M, Bateman M, Klatt NE, et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol. 1994;12(3):601-7.
62. Strasser F, Bruera ED. Update on anorexia and cachexia. Hematol Oncol Clin North Am. 2002;16(3): 589-617.
63. Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol. 1994;12(1): 213-25.
64. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89(2):381-410.
65. Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol. 2010;26(2):146-51.
66. Braun TP, Marks DL. Pathophysiology and treatment of in flammatory anorexia in chronic disease. J Cachex Sarcopenia Muscle. 2010;1(2):135-45.
67. Blum D, Omlin A, Baracos VE, Solheim TS, Tan BH, Stone P, Kaasa S, Fearon K, Strasser F, European Palliative Care Research Collaborative. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol. 2011;80:114-44.
68. Behl D, Jatoi A. Pharmacological options for advanced cancer patients with loss of appetite and weight. Expert Opin Pharmacother. 2007;8(8):1085-90.
69. Jatoi A. Pharmacologic therapy for the cancer anorexia/weight loss syndrome: a data-driven, practical approach. J Support Oncol. 2006;4(10):499-502.
70. Jatoi Jr. A, Loprinzi CL. Current management of cancer-associated anorexia and weight loss. Oncology (Williston Park). 2001;15(4):497-502.
71. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep. 1985;69(7-8):751-4.
72. McCarthy HD, Crowder RE, Dryden S, Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol. 1994;265(1-2): 99-102.
73. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2005;18(2):CD004310.
74. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20(2):567-73.
75. Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LM, Goldberg RM, Tschetter LK, Hatfield AK, Morton RF. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol. 1993;11(4): 762-7.
76. Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer. 2010;18(8): 951-6.
77. Stone PC, Minton O. Cancer-related fatigue. Eur J Cancer. 2008;44(8):1097-104.
78. Radbruch L, Strasser F, Elsner F, Gonçalves JF, Løge J, Kaasa S, Nauck F, Stone P, Research Steering Committee of the European Association for Palliative Care (EAPC). Fatigue in palliative care patients-an EAPC approach. Palliat Med. 2008;22(1):13-32.
79. Davis MP, Khoshknabi D, Yue GH. Management of fatigue in cancer patients. Curr Pain Headache Rep. 2006;10(4):260-9.
80. Oh HS, Seo WS. Systematic review and meta-analysis of the correlates of cancer-related fatigue. Worldviews Evid Based Nurs. 2011;8(4):191-201.
81. Yavuzsen T, Davis MP, Ranganathan VK, Walsh D, Siemionow V, Kirkova J, Khoshknabi D, Lagman R, LeGrand S, Yue GH. Cancer-related fatigue: central or peripheral? J Pain Symptom Manage. 2009;38(4):587-96.
82. Seyidova-Khoshknabi D, Davis MP, Walsh D. Review article: a systematic review of cancer-related fatigue measurement questionnaires. Am J Hosp Palliat Care. 2011;28(2):119-29.
83. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. 2008;100(16):1155-66.
84. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010;7:CD006704.